Clinical Trials Logo

Filter by:
NCT ID: NCT06006741 Recruiting - Clinical trials for Multiple Myeloma in Remission

Universal CAR-T Cells Targeting Multiple Myeloma

Start date: October 31, 2023
Phase: Phase 1
Study type: Interventional

The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.

NCT ID: NCT06006689 Recruiting - Clinical trials for Diabetic Kidney Disease

Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

Start date: September 4, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and Safety of QiShen YiQi Dripping Pills in the treatment of Diabetic Kidney Disease (syndrome of Qi deficiency with blood stasis)

NCT ID: NCT06006650 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

The aim of this study was to investigate the efficacy and safety of pembrolizumab combined with albumin paclitaxel and cisplatin versus albumin paclitaxel and cisplatin or 5-fluorouracil and cisplatin in neoadjuvant therapy for stage II-IVa resectable esophageal squamous cell carcinoma. The study plans to enroll 114 eligible patients who will be randomly assigned in a 1:1:1 ratio to receive 3 cycles of neoadjuvant immunochemotherapy (pembrolizumab plus albumin paclitaxel and cisplatin;Pembrolizumab plus 5-fluorouracil and cisplatin) or chemotherapy alone (5-fluorouracil and cisplatin), followed by surgery 3 weeks later, followed by 16 cycles of adjuvant immunotherapy (pembrolizumab).Patients were followed up for efficacy and safety during treatment.Tumor evaluation will be performed at screening, after neoadjuvant therapy, before surgery, and after adjuvant therapy until objective disease progression is confirmed.

NCT ID: NCT06006611 Active, not recruiting - COVID-19 Clinical Trials

Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study

Start date: August 5, 2023
Phase:
Study type: Observational

The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.

NCT ID: NCT06006403 Recruiting - Clinical trials for Acute Myeloid Leukemia

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Start date: August 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of targeting CD123 CAR-NK cell preparations in Relapsed/refractory acute myeloid leukemia (AML) or blastocytic plasmacytoid dendritic cell neoplasm (BPDCN). The pharmacokinetic characteristics of CAR-NK cell preparations for the treatment of patients with Relapsed/refractory acute myeloid leukemia or blastocytic plasmacytoid dendritic cell neoplasm were obtained and the recommended dose.

NCT ID: NCT06006390 Recruiting - Breast Cancer Clinical Trials

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Start date: September 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.

NCT ID: NCT06006338 Recruiting - Liver Cancer Clinical Trials

3D Printed Models for Liver Surgery

Start date: September 15, 2023
Phase: Phase 1
Study type: Interventional

Comprehensive preoperative planning and real-time intraoperative guidance are essential prerequisites for achieving precise liver resection. In pursuit of this goal, the investigators have developed innovative 3D printed liver models utilizing a physically crosslinked self-healing elastomer created through the copolymerization of 4-acryloylmorpholine (ACMO) and methoxy poly (ethylene glycol) acrylate (mPEGA). These printed models exhibit exceptional healing capabilities, efficiently restoring their structure within minutes at room temperature, and rapidly recovering within moments after being incised. Herein, the investigators aim to assess the viability of employing these 3D printed liver models as instrumental tools in designing the optimal surgical approach through an iterative trial-and-error methodology. Concurrently, the investigators aim to determine whether the integration of these 3D printed models into conventional methods (contrast-enhanced CT or MRI) can enhance the safety, ease, and efficiency of hepatic resection procedures.

NCT ID: NCT06006325 Recruiting - Sepsis Clinical Trials

Electroacupuncture Modulates SPMs Metabolism and Respiratory Symptoms in Patients With Sepsis Complicating ARDS

Start date: August 20, 2023
Phase: N/A
Study type: Interventional

In this interventional clinical trial, researchers will administer electroacupuncture versus sham electroacupuncture to sepsis patients with ARDS and collect objective outcome measures. The study will be divided into 2 groups. The EA group will receive electroacupuncture and the SHAM-EA group will receive sham electroacupuncture. The purpose of this study is to investigate the effect of electroacupuncture on the synthesis of SPMs in sepsis patients with ARDS.

NCT ID: NCT06006312 Recruiting - Diabetes Mellitus Clinical Trials

Establishment and Clinical Application of Pancreatic Endocrine and Exocrine Function Tests

Start date: August 2023
Phase:
Study type: Observational

The goal of this observational study is to improve the epidemiological data of pancreatic exocrine insufficiency in China, determine the FE-1 cut-off value for the classification of PEI, and explore the characteristic differences between T3cDM and type 2 diabetes mellitus in clinical symptoms and laboratory indicators.

NCT ID: NCT06006234 Enrolling by invitation - Depression, Anxiety Clinical Trials

Analysis of Anxiety and Depression Among Elderly People

Start date: July 1, 2023
Phase:
Study type: Observational

This study is a single-center, cross-sectional, and survey study. Through questionnaire surveys, information about the anxiety and depression status of residents of elderly care institutions in Zhejiang Province is collected. Through multi-factor analysis, the relevant influencing factors that affect their psychological status are clarified. The happy old age society provides reference opinions.